Nonacog beta pegol is a recombinant coagulation Factor IX derivative used to treat hemophilia B. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation.
- Mechanism
- Curator reviewed · 3 references
Nonacog beta pegol is activated by factor IXa and the tissue complex factor VII, whereby the peptide, including the 40kDa PEG moiety, is cleaved off. The resulting product from this activation process is recombinant factor IX with the same biological activity as endogenous coagulation factor IXa. The activated coagulation factor IX, in combination with factor VIIIa, activates the coagulation factor X to trigger the coagulation cascade and promote the conversion of prothrombin into thrombin. Thrombin drives the conversion of fibrinogen into fibrin for clot formation.
- Primary indication
- Nonacog beta pegol is indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for control and prevention of bleeding episodes as well as control and prevention of bleeding in...Curator reviewed · 5 structured indications
- First approval
- Canada, 2017 · European Union, 2020
- Also known as
- Coagulation Factor IX (Recombinant), GlycoPEGylated
- Code names
- N9-GP
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Nonacog beta pegol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account